Noninvasive Evaluation of Cardiac Allograft Vasculopathy (CAVII)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01305382
First received: February 25, 2011
Last updated: March 13, 2013
Last verified: March 2013
  Purpose

Abnormal peripheral endothelial function and alterations in circulating biomarkers that are associated with endothelial activation and inflammation correlate with angiographic evidence of cardiac allograft vasculopathy, defined as greater than 25% stenosis in a major coronary artery.


Condition
Cardiac Allograft Vasculopathy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Noninvasive Evaluation of Cardiac Allograft Vasculopathy in Heart Transplant Recipients II

Resource links provided by NLM:


Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • Stenosis of a major coronary artery greater than 25% on coronary angiogram. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
    The purpose of this study is to determine whether certain levels and patterns of expression of biomarkers known to be related to endothelial function and abnormalities in peripheral artery function are predictive of the presence of transplant vasculopathy.


Estimated Enrollment: 80
Study Start Date: October 2008
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
Heart Transplant Cohort
This group consist of transplant subjects within 10 years of heart transplant
Heart Failure Sub group
Consist of subjects with advanced heart failure (NYHA class III and IV)
Healthy Volunteer
This groups consist of healthy individuals

Detailed Description:

Cardiac transplantation has become the established treatment of choice for eligible patients with end-stage heart failure. Cardiac allograft vasculopathy (CAV) is a major and potentially preventable limitation to long-term survival in cardiac transplant recipients. CAV affects up to 50% of recipients by year 5, though intimal thickening is present in up to 58% one year after transplantation. CAV is characterized by diffuse, concentric intimal hyperplasia, involving both epicardial and intramyocardial coronary arteries. In its most advanced stages, CAV is not amenable to standard revascularization procedures making the only cure re-transplantation. Given the limited donor pool and poor outcome, re-transplantation is not an option for all patients. CAV tends to be a silent process. Due to denervation of the transplanted heart, transplant recipients do not typically have chest pain, and thus the first symptoms of CAV may be those of heart failure or sudden cardiac death. Traditional risk factors are important in predicting the development of CAV, however non-traditional risk factors appear equally important and include cellular and humoral rejection, graft ischemia at the time of implantation, and cytomegalovirus (CMV).

Despite the specific inciting event, the end result is endothelial dysfunction, which is the predecessor to CAV. Methods to detect, prevent, and treat endothelial dysfunction and subsequently CAV are few. The rapidity with which it develops, however, affords a great opportunity to study mechanisms and potential interventions in a relatively short period of time.

Chronic inflammation and immune activation and subsequent endothelial injury are felt to immunopathogenic in the development of CAV. Endothelial activation is a precursor to the development of transplant vasculopathy, and multiple biomarkers have been shown to correlate with the presence of endothelial dysfunction in transplant vasculopathy. (fig. 1) Endothelial activation, as determined by the presence of adhesion molecules, begins hours after brain death in a donor. VCAM-1, e-selectin, and p-selectin are expressed early after brain death in the donor and are elevated throughout transplantation in the recipient as a response to injury in the donor heart. P-selectin and VCAM remain elevated while e-selectin gradually decrease over three months. There is data suggesting that p-selectin and VCAM remain elevated up to 2 years after transplantation, suggesting persistent inflammation and immune activation after transplant. Furthermore, nitric oxide is the principal mediator of protective effects on the endothelium. The nitric oxide pathway is essential in maintaining vascular integrity in cardiac recipients, and inhibition of this pathway accelerates intimal thickening and worsens endothelial function caused by rejection. Intimal thickening is a marker of endothelial dysfunction and a precursor to the development of CAV.

Thus, these markers and others involved in atherogenesis, remodeling, immune activation and endothelial activation, may provide a useful modality in predicting the presence of vasculopathy. In addition, studying various components of the process, eg. inflammation and injury, will provide much needed information regarding targets for therapy.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Heart Transplant subjects within 10 years of heart transplantation Subjects with advanced heart failure Healthy Volunteers

Criteria

Inclusion Criteria:

  • Age ≥ 18 years
  • Provide informed consent
  • Presence of advanced heart failure (NYHA class III, IV) on medical therapy
  • Patients with advanced heart failure on transplant list
  • Transplant recipients undergoing invasive evaluation for coronary artery disease within 6 months to ten years post transplantation

Exclusion Criteria:

  • Current tobacco use
  • History of chronic kidney disease
  • Active infection
  • History of organ transplantation
  • Diabetes Mellitus
  • History of Hypertension
  • Known coronary artery disease
  • Connective tissue disorder
  • History of hyperlipidemia
  • History of Migraine or Chronic unevaluated headaches
  • Patients with chronic kidney disease stage 4 defined as GFR<30 mL/min/1.73 m2 or acute renal failure
  • Patients with acute rejection, Grade 3A or greater
  • Active infection
  • Re-transplant or Multi-organ transplant recipient
  • Surgery within 3 months prior to enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01305382

Locations
United States, Minnesota
Cardiology Division, University of Minnesota
Minneapolis, Minnesota, United States, 55455
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Investigators
Principal Investigator: Monica M Colvin-Adams, MD, MS Cardiology, University of Minnesota
  More Information

No publications provided

Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT01305382     History of Changes
Other Study ID Numbers: 0808M43361
Study First Received: February 25, 2011
Last Updated: March 13, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by University of Minnesota - Clinical and Translational Science Institute:
Cardiac Allograft Vasculopathy

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on October 19, 2014